Citigroup
LXRX icon

Citigroup’s Lexicon Pharmaceuticals LXRX Stock Holding History

Citigroup’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,000
Closed -$4K – 7705
2019
Q4 		$4K Hold
1,000
– – ﹤0.01% 7454
2019
Q3 		$3K Sell
1,000
-400
-29% -$1.24K ﹤0.01% 7467
2019
Q2 		$9K Sell
1,400
-12,100
-90% -$72.4K ﹤0.01% 7339
2019
Q1 		$75K Buy
13,500
+6,300
+88% +$38.3K ﹤0.01% 6002
2018
Q4 		$48K Sell
7,200
-10,400
-59% -$84.3K ﹤0.01% 6278
2018
Q3 		$188K Sell
17,600
-1,400
-7% -$16K ﹤0.01% 5321
2018
Q2 		$228K Buy
19,000
+13,500
+245% +$138K ﹤0.01% 4925
2018
Q1 		$47K Buy
5,500
+1,900
+53% +$17.6K ﹤0.01% 6211
2017
Q4 		$36K Sell
3,600
-19,200
-84% -$199K ﹤0.01% 6394
2017
Q3 		$280K Buy
22,800
+21,500
+1,654% +$318K ﹤0.01% 4689
2017
Q2 		$21K Sell
1,300
-24,800
-95% -$384K ﹤0.01% 6248
2017
Q1 		$374K Buy
26,100
+14,400
+123% +$214K ﹤0.01% 4115
2016
Q4 		$162K Buy
11,700
+11,500
+5,750% +$185K ﹤0.01% 5457
2016
Q3 		$4K Buy
+200
New +$3.22K ﹤0.01% 6825

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citigroup's LXRX Position: Q1 2026 in Review

Citigroup increased its Lexicon Pharmaceuticals (LXRX) stake by 82% in Q1 2026, buying an estimated $109K and bringing the position to 166,398 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #3875.

Citigroup first reported a position in LXRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.86M in Q3 2018. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Citigroup held 166,398 shares of Lexicon Pharmaceuticals worth $260K as of Q1 2026.
  • Citigroup bought 74,728 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $109K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3875 holding.
  • Citigroup first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Lexicon Pharmaceuticals position peaked at $2.86M in Q3 2018.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.